Business Context and Reporting Period
This Form 8-K filing by Savara Inc. (Savara) reports a material event occurring on April 26, 2019. The filing details the entry into a new Manufacture and Supply Agreement with GEMABIOTECH SAU (GEMA), a corporation organized under the laws of Argentina.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on the terms of a contractual agreement rather than financial performance metrics.
Material Changes and Agreement Terms
The primary material change is the execution of a new agreement superseding a prior Supply and License Agreement dated December 10, 2012. Key terms include:
- Scope: GEMA will exclusively manufacture and supply the active pharmaceutical ingredient (API) for Savara's Molgradex product for commercial sale, clinical studies, and R&D.
- Regulatory Compliance: GEMA is obligated to obtain necessary FDA and regulatory approvals for commercial manufacturing.
- Asset Transfer: GEMA transferred all rights to the master cell bank and working cell bank to Savara.
- Payment Structure:
- Agreed price per vial of 1 gram of API.
- Milestone payments triggered by: effective date, developmental activities, successful FDA audit, and marketing approval.
- Single-digit percentage royalty on annual net sales in countries where the product is commercialized.
- Term: Runs until the 20th anniversary of the first marketing approval in any country, with options for 12-month extensions.
- Termination: Savara may terminate immediately for reasons including market withdrawal, regulatory failure, or repeated batch specification failures.
Guidance, Outlook, and Risks
The filing does not contain updated financial guidance or general outlook commentary. However, it outlines specific risks and contingencies tied to the agreement:
- Regulatory Risk: The agreement's viability depends on GEMA achieving FDA compliance and obtaining marketing approvals.
- Quality Risk: The contract allows for immediate termination if three or more API batches fail to conform to specifications within a six-month period.
- Market Risk: Royalty obligations cease if a biosimilar of the product is first sold in a specific country.
Investor Verification Checklist
- Verify the specific "agreed upon price per vial" and the exact "single digit percentage" royalty rate, as these figures are not disclosed in this summary.
- Confirm the status of GEMA's FDA audit and regulatory compliance efforts for commercial manufacturing.
- Review the full text of the Manufacture and Supply Agreement when filed as an exhibit to the Form 10-Q for the quarter ended March 31, 2019.
- Monitor the timeline for the first marketing approval of Molgradex to determine the start of the 20-year agreement term.